Strs Ohio Has $1.86 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Strs Ohio grew its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 6.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 15,082 shares of the specialty pharmaceutical company’s stock after purchasing an additional 963 shares during the period. Strs Ohio’s holdings in Jazz Pharmaceuticals were worth $1,855,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. International Assets Investment Management LLC acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at $7,201,000. DekaBank Deutsche Girozentrale grew its stake in shares of Jazz Pharmaceuticals by 94.2% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 91,540 shares of the specialty pharmaceutical company’s stock valued at $11,210,000 after acquiring an additional 44,414 shares in the last quarter. Los Angeles Capital Management LLC grew its position in shares of Jazz Pharmaceuticals by 558.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock worth $41,780,000 after purchasing an additional 273,764 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Jazz Pharmaceuticals by 40.8% during the 3rd quarter. AQR Capital Management LLC now owns 179,111 shares of the specialty pharmaceutical company’s stock worth $23,184,000 after purchasing an additional 51,871 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC grew its position in shares of Jazz Pharmaceuticals by 242.8% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company’s stock worth $35,023,000 after purchasing an additional 191,648 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $109.94 on Friday. Jazz Pharmaceuticals plc has a fifty-two week low of $106.61 and a fifty-two week high of $146.70. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. The firm has a market capitalization of $6.93 billion, a P/E ratio of 17.96, a P/E/G ratio of 1.51 and a beta of 0.59. The company’s 50 day moving average price is $119.81 and its two-hundred day moving average price is $122.48.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. On average, equities analysts forecast that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was acquired at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at $3,342,063.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Philip L. Johnson acquired 12,000 shares of the stock in a transaction dated Friday, March 1st. The shares were bought at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The disclosure for this purchase can be found here. Company insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of analyst reports. Stifel Nicolaus increased their price target on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Royal Bank of Canada reissued an “outperform” rating and set a $195.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Truist Financial reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, March 22nd. Finally, Barclays reduced their price objective on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating on the stock in a research note on Friday, March 1st. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $195.08.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.